Life Extension Skin Care Sale

Insomnia References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Kessler RC, Berglund PA et al. Insomnia and the Performance of US Workers: Results from the American Insomnia Survey. Sleep, 2011; 34(9): 1161-1171.
  2. Shatzmiller RA and Benbadis SR. Insomnia. Available at: http://emedicine.medscape.com/article/1187829-overview Revised 2/12/2012; Accessed 4/19/2012.
  3. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Revised. 2001.
  4. Terauchi M, Hiramitsu S, Akiyoshi M, et al. Associations between anxiety, depression and insomnia in peri- and post-menopausal women. Maturitas. 2012 May;72(1):61-5.
  5. Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Compr Psychiatry. 1998 Jul-Aug;39(4):185-97.
  6. Kakizaki M, Inoue K, Kuriyama S, et al. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer. 2008 Jul 8;99(1):176-8. Epub 2008 Jun 10.
  7. Verkasalo PK, Lillberg K, Stevens RG, et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 2005 Oct 15;65(20):9595-600.
  8. Philips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? J Clin Sleep Med. 2007 Aug 15;3(5):489-94.
  9. Chien KL, Chen PC, Hsu HC, et al. Habitual sleep duration and insomnia and the risk of cardiovascular events and all-cause death: report from a community-based cohort. Sleep. 2010 Feb;33(2):177-84.
  10. Hublin C, Partinen M, Koskenvuo M, et al. Heritability and mortality risk of insomnia-related symptoms: a genetic epidemiologic study in a population-based twin cohort. Sleep. 2011 Jul 1;34(7):957-64.
  11. Kripke DF, Langer RD, and Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012 Feb 27;2(1):e000850. Print 2012.
  12. Yang CM and Lin SC. Maladaptive Sleep Hygiene Practices in Good Sleepers and Patients with Insomnia. Journal of Health Psychology, 2010; 15(1): 147-55.
  13. Lande RG and Gragnani C. Nonpharmacological Approaches for the Treatment of Insomnia. The Journal of the American Osteopathic Association, 2010; 110(12): 695-701.
  14. Xu J, Jiang X et al. Propofol-Induced Sleep: Efficacy and Safety in Patients with Refractory Chronic Insomnia. Cell BiochemBiophys, 2011 Jul;60(3): 161-6.
  15. National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Facts About Insomnia. October 1995. Available at: http://www.nhlbi.nih.gov/health/public/sleep/insomnia.txt. Accessed 6/14/2012.
  16. Ellis JG, Gehrman P, Espie CA, et al. Acute insomnia: current conceptualizations and future directions. Sleep Med Rev. 2012 Feb;16(1):5-14.
  17. Roth T and Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone. 2003;5(3):5-15.
  18. Bonnet MH and Arand DL. Hyperarousal and Insomnia: State of the Science. Sleep Medicine Reviews, 2010;14:9-15.
  19. Zhang J, Ma RC et al. Relationship of Sleep Quantity and Quality with 24-Hour Urinary Catecholamines and Salivary Awakening Cortisol in Healthy Middle-Aged Adults. Sleep, 2011; 34(2): 225-233.
  20. Chiodini I, Scillitani A. [Role of cortisol hypersecretion in the pathogenesis of osteoporosis]. RecentiProg Med. 2008 Jun;99(6):309-13.
  21. Butcher SK, Killampalli V, Lascelles D, et al. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity. Aging Cell. 2005 Dec;4(6):319-24.
  22. Duong M, Cohen JI, and Convit A. h cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine. 2012 Feb;41(1):76-81.
  23. Irwin MR, Wang M et al. Sleep Deprivation and Activation of Morning Levels of Cellular and Genomic Markers of Inflammation. Archives of Internal Medicine, 2006; 166: 1756-1762.
  24. Smith MT, Quartana PJ et al. Mechanisms By Which Sleep Disturbance Contributes to Osteoarthritic Pain: A Conceptual Model. Current Pain and Headache Reports, 2009; 13: 447-54.
  25. UAB News. [Lollar J.] Sleep debt hikes risk of stroke symptoms despite healthy BMI. 6/11/2012 Available at: http://www.uab.edu/news/latest/item/2483-sleep-debt-hikes-risk-of-stroke-symptoms-despite-healthy-bmi?tmpl=component&print=1 Accessed 6/21/2012.
  26. Morin CM, LeBlanc M et al. Epidemiology of Insomnia: Prevalence, Self-Help Treatments, Consultations and Determinants of Self-Help Seeking Behaviors. Sleep Medicine, 2006: 123-30.
  27. Buysse DJ, Germain A et al. Diagnosis, Epidemiology and Consequences of Insomnia. Primary Psychiatry, 2005; 12(8): 37-44.
  28. Baroni A, Hernandez M, Grant MC, Faedda GL. Sleep Disturbances in Pediatric Bipolar Disorder: A Comparison between Bipolar I and BipolarNOS. Front Psychiatry. 2012;3:22. Epub 2012 Mar 20.
  29. Singareddy R, Vgontzas AN et al. Risk Factors for Incident Chronic Insomnia: A General Population Prospective Study. Sleep Medicine, 2012: 346-53.
  30. Sato M, Yamadera W et al. Clinical Efficacy of Individual Cognitive Behavior Therapy for Psychophysiological Insomnia in 20 Outpatients. Psychiatry and Clinical Neurosciences, 2010; 64: 187-195.
  31. Bastien CH, St-Jean G, et al. Chronic Psychophysiological Insomnia: Hyperarousal and/or Inhibition Deficits? An ERPs Investigation. Sleep, 2008; 31(6): 887-98.
  32. Espie CA. Insomnia: Conceptual Issues in the Development, Persistence and Treatment of Sleep Disorder in Adults. Annual Reviews in Psychology, 2002; 53: 215-43.
  33. Sivertsen B, Krokstad S et al. The Epidemiology of Insomnia: Associations with Physical and Mental Health. Journal of Psychosomatic Research, 2009: 109-116.
  34. Taylor DJ, Mallory LJ et al. Comorbidity of Chronic Insomnia with Medical Problems. Sleep, 2007; 30(2): 213-8.
  35. Geyer JD, Ruiter ME et al. Management of Insomnia in Patients with Chronic Obstructive Pulmonary Disease. Sleep Medicine Clinics, 2008: 379-87.
  36. Katz DA and McHorney CA. Clinical Correlates of Insomnia in Patients with Chronic Illness. Archives of Internal Medicine, 1998; 158: 1099-107.
  37. George CF. Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep. 2000 Feb 1;23 Suppl1:S31-5; discussion S36-8.
  38. Woods NF and Mitchell ES. Symptoms During the Perimenopause: Prevalence, Severity Trajectory, and Significance in Women's Lives. The American Journal of Medicine, 2005; 118: 14-24.
  39. Silva BH, Martinez D et al. A Randomized, Controlled Pilot Trial of Hormone Therapy for Menopausal Insomnia. Archives of Women's Mental Health, 2011; 14: 505-8.
  40. Saletu-Zyhlarz G, Anderer P et al. Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen–progestogen combination (Climodien_, Lafamme_) versus estrogen alone. Journal of Sleep Research, 2003; 12: 239-54.
  41. Hammoud AO, Walker JM et al. Sleep Apnea, Reproductive Hormones and Quality of Sexual Life in Severely Obese Men. Obesity, 2011; 19(6): 1118-1123.
  42. Barrett-Connor E, Dam TT, Stone K, et al. The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J ClinEndocrinolMetab. 2008 Jul;93(7):2602-9.
  43. Canguven O, Salepci B, Albayrak S, et al. Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea? Arch ItalUrolAndrol. 2010 Dec;82(4):143-7.
  44. Neikrug AB and Ancoli-Israel S. Sleep Disorders in the Older Adult-A Mini Review. Gerontology, 2010; 56: 181-9.
  45. Moghadam-Kia S and WerthVp et al. Prevention and Treatment of Systemic Glucocorticoid Side Effects. International Journal of Dermatology, 2010; 49: 239-48.
  46. Nerbass FB, Pedrosa RP et al. Calcium Channel Blockers are Independently Associated With Short Sleep Duration in Hypertensive Patients with Obstructive Sleep Apnea. Journal of Hypertension, 2011; 29(6): 1236-41.
  47. Bercovitch RS and Tsai SC. Respiratory Medications and Sleep. Current Respiratory Care Report, 2012: 123-30.
  48. Roehrs T and Roth T. Caffeine: Sleep and Daytime Sleepiness. Sleep Medicine Reviews, 2008; 12: 153-62.
  49. Youngberg MR, Karpov IO et al. Clinical and Physiological Correlates of Caffeine and Caffeine Metabolites in Primary Insomnia. J Clin Sleep Med. 2011;7(2):196-203.
  50. Jaehne A, Loessl B et al. Effects of Nicotine on Sleep During Consumption, Withdrawal, and Replacement Therapy. Sleep Medicine Reviews, 2009; 13: 363-77.
  51. Mills EJ, Wu P et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tobacco Induced Diseases, 2010; 8(8): 8.
  52. Hendler RA, Ramchandani VA, Gilman J, et al. Stimulant and Sedative Effects of Alcohol. Curr Top BehavNeurosci. 2013; 13: 489-509. doi: 10.1007/7854_2011_135.
  53. Brower KJ, Myra Kim H, Strobbe S, et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. oholClinExp Res. 2008 Aug;32(8):1429-38.
  54. Kolla BP and Auger RR. Jet Lag and Shift Work Sleep Disorders: How to Help Reset the Internal Clock. Cleveland Clinic Journal of Medicine, 2011; 78(10): 675-84.
  55. Punjabi NM. The Epidemiology of Adult Obstructive Sleep Apnea. Proc Am ThoracSoc, 2008; 5(2):136-43.
  56. Drager LF, PolotskyVY et al. Obstructive Sleep Apnea: An Emerging Risk Factor for Atherosclerosis. Chest, 2011; 140: 534-42.
  57. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart healthy study. Circulation. 2010;122(4):352-60.
  58. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated with Resistant Hypertension. Hypertension, 2011; 58:811-817.
  59. Aronsohn RS, Whitmore H et al. Impact of Untreated Obstructive Sleep Apnea on Glucose control in Type 2 Diabetes. American Journal of Respiratory Critical Care, 2010; 181; 507-513.
  60. Nieto FJ, Peppard PE, Young T, et al. Sleep disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J RespirCrit Care Med. 2012 May 20. [Epub ahead of print]
  61. Yaggi HK, Concato J. Obstructive Sleep Apnea as a Risk Factor for Stroke and Death. The New England Journal of Medicine, 2005; 353(19): 2034-41.
  62. Mastin DF, Bryson J, Corwyn R. Assessment of sleep hygiene using the Sleep Hygiene Index. J Behav Med. 2006;29(3):223-7.
  63. Hoch CC, Reynolds CF et al. Protecting Sleep Quality in Later Life: A Pilot Study of Bed Restriction and Sleep Hygiene. Journal of Gerontology, 2001; 56 (1): P52-9.
  64. McCurry SM, Logsdon RG, Teri L, et al. Sleep disturbances in caregivers of persons with dementia: contributing factors and treatment implications. Sleep Med Rev. 2007;11(2):143-53.
  65. Randall S, Roehrs TA et al. Over-the-Counter Sleep Aid Medications and Insomnia. Primary Psychiatry, 2008; 15(5): 52-58.
  66. Lieberman JA. Update on the Safety Considerations in the Management of Insomnia with Hypnotics: Incorporating Modified-Release Formulations Into Primary Care. Primary Care Companion, 2007; 9(1): 25-31.
  67. Buscemi N, Vandermeer B et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTS. Journal of General Internal Medicine, 2007; 22: 1335-50.
  68. Holbrook AM, Crowther R et al. Meta-analysis of Benzodiazepine Use in the Treatment of Insomnia. Canadian Medical Association Journal, 2000; 162(2): 225-33.
  69. Ancoli-Israel S, Walsh JK et al. Zaleplon, A Novel Nonbenzodiazpeine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. Primary Care Companion, 1999; 1(4): 114-120.
  70. Cluydts R. A Breakthrough in the Pharmacological Management of Insomnia: Overview of the Clinical Profile of Zaleplon. Primary Care Companion, 2002; 4: 46-8.
  71. Hindmarch I, Legangeneux E et al. A Double-Blind, Placebo-Controlled Investigation of the Residual Psychomotor and Cognitive Effects of Zolpidem-MR in Healthy Elderly Volunteers. British Journal of Pharmacology, 2006; 62(5): 538-45.
  72. Krystal AD, Erman M et al. Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg. Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients with Chronic Primary Insomnia: A 6-month, Randomized, Double-Blind, Placbo-Controlled, Parallel-Group Multi-Center Study. Sleep, 2008; 31(1): 79-90.
  73. Roth T, Walsh JK et al. An Evaluation of the Safety and Efficacy of Eszopiclone over 12 Months in Patients with Chronic Primary Insomnia. Sleep Medicine, 2005; 6(6): 487-95.
  74. Ancoli-Israel S, Krystal AD et al. A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia. Sleep, 2010; 33(2): 225-234.
  75. Hoque R and Chesson AL. Zolpidem-Induced Sleepwalking, Sleep Related Eating Disorder and Sleep-Driving. Fluorine-18 Positron Emission Tomography Analysis, and a Literature Review of Other Unexpected Clinical Effects of Zolpidem. Journal of Clinical Sleep Medicine, 2009; 5(5): 471-6.
  76. Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007 Aug 21;7:42.
  77. Weber J, Siddiqui MA, WagstaffAJ, et al. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010 Aug;24(8):713-20.
  78. Aurón Zaltzman D. [Amitriptyline hydrochloride in the treatment of anxiety and insomnia and as a tranquilizer]. NeurolNeurocirPsiquiatr. 1976;17(3):165-9.
  79. Galecki P, ski A, Talarowska M. et al. [Efficacy of trazodone in the treatment of insomnia]. Pol MerkurLekarski. 2010 Jun;28(168):509-12.
  80. Roth T, Rogowski R et al. Efficacy and Safety of Doxepin 1 mg, 3 mg and 6 mg in Adults With Primary Insomnia. Sleep, 2007; 30(11): 1557-64.
  81. Krystal AD, Durrence HH et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Primary Insomnia. Sleep, 2010: 33(11): 1553-61.
  82. Walsh JK, Erman M et al. Subjective Hypnotic Efficacy of Trazodone and Zolpidem in DSMRIII-R Primary Insomnia. Human Psychopharmacology, 1998; 13: 191-198.
  83. Mendelson WB. A Review of the Evidence for the Efficacy and Safety of Trazodone in Insomnia. Journal of Clinical Psychiatry, 2005; 66: 469-76.
  84. Schewitzer PK, Curry Dt et al. Pharmacological treatment of Insomnia. Clinical Handbook of Insomnia, 2010: 297-316.
  85. Miyamoto M. [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600.
  86. Turek FT and Gilette MU. Melatonin, Sleep and Circadian Rhythms: Rationale for Development of Specific Melatonin Agonists. Sleep Medicine, 2005; 5: 523-32.
  87. Kato K, Hirai K et al. Neurochemical Properties of Ramelteon (TAK-375), a Selective MT1/Mt2 Receptor Agonist. Neuropharmacology, 2005; 48: 301-10.
  88. Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med Rev. 2008;12(4):319-32.
  89. Erman M, Seiden D et al. An Efficacy, Safety and Dose-Response Study of Ramelteon in Patients with Chronic Primary Insomnia. Sleep Medicine, 2006; 7: 17-24.
  90. Borja NL and Daniel KL. Ramelteon for the Treatment of Insomnia. Clinical Therapeutics, 2006; 28(10): 1540-55.
  91. Zammit G, Erman M et al. Evaluation of the Efficacy and Safety of Ramelteon in Subjects with Chronic Insomnia. Journal of Clinical Sleep Medicine, 2007; 3(5): 495-504.
  92. Ochoa-Sanchez R, Comai S et al. Promotion of Non-Rapid-Eye-Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT2 Melatonin Receptor Ligand. Journal of Neuroscience, 2011; 31(50): 18439-18452.
  93. Spadoni G, Bedini A et al. Melatonin Receptor Agonists: New Options for Insomnia and Depression Treatment. CNS Neuroscience and Therapeutics, 2011; 17: 733-41.
  94. Nonogaki K. Serotonin conflict in sleep-feeding. VitamHorm. 2012;89:223-39.
  95. Landolt HP and Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009 May;29(9):1795-809.
  96. Xiong Y, Ullman B et al. Synthesis and in Vivo Evaluation of Phenethylpiperazine Amides: Selective 5-HydroxyTryptamine2A Receptor Antagonists for the Treatment of Insomnia. Journal of Medicinal Chemistry, 2010; 53: 5696-706.
  97. Al-Shamma HA, Anderson C et al. Nelotanserin, a Novel Selective 5-Hydroxytryptamine2A Inverse Antagonist for the Treatment of Insomnia. The Journal of Pharmacology and Experimental Therapeutics, 2010; 332(1): 281-90.
  98. Cardinali DP, Srinivasan V et al. Melatonin and its Analogs in Insomnia and Depression. Journal of Pineal Research, 2012; 52: 365-75.
  99. Geijlswijk IM, Heijden KB et al. Dose Finding of Melatonin for Chronic Idiopathic Childhood Onset Insomnia: a RCT. Psychopharmacology, 2010; 212: 379-91.
  100. Lemoine P, Wage AG et al. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integrated Blood Pressure Control, 2012; 5: 9-17.
  101. Garfinkel D, Zorin M et al. Efficacy and Safety of Prolonged-Release Melatonin in Insomnia Patients with Diabetes: A Randomized, Double-Blind, Crossover Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011; 4: 307-13.
  102. Richard DM, Dawes MA et al. L-Tryptophan: Basic Metabolic Functions, Behavioral research and Therapeutic Indications. International Journal of Tryptophan Research, 2009; 2: 45-60.
  103. Peuhkuri K, Sihvola N, and Korpela R. Diet promotes sleep duration and quality. Nutr Res. 2012 May;32(5):309-19.
  104. Paredes SD, Barriga CM et al. Assessment of the Potential Role of Tryptophan as the Precursor of Serotonin and Melatonin for the Aged Sleep-Wake Cycle and Immune Function: Streptopeliarisioria as a Model. International Journal of Tryptophan Research, 2009a; 2: 23-36.
  105. Hartmann E, Cravens J et al. Hypnotic Effects of L-Tryptophan. Archives of General Psychiatry, 1974; 31: 394-7.
  106. Paredes SD, Marchena AM et al. Rhythm, Core and Peripheral Temperatures and Interleukin Levels in the Ringdove: Changes with Age. Journal of Gerontology, 2009b; 64A(3): 340-50.
  107. Hajak G, Huether G, Blanke J, et al. The influence of intravenous L-tryptophan on plasma melatonin and sleep in men. Pharmacopsychiatry. 1991 Jan;24(1):17-20.
  108. Silber BY and Schmitt JA. Effects of Tryptophan Loading on Human Cognition, Mood and Sleep. NeurosciBiobehav Rev, 2010; 34: 387-407.
  109. Durlach J, Pagès N, Bac P, et al. Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion. Magnes Res. 2002 Mar;15(1-2):49-66.
  110. Omiya K, Akashi YJ, Yoneyama K, et al. Heart-rate response to sympathetic nervous stimulation, exercise, and magnesium concentration in various sleep conditions. Int J Sport NutrExercMetab. 2009 Apr;19(2):127-35.
  111. Rondanelli M, Opizzi A et al. The Effect of Melatonin, Magnesium and Zinc on Primary Insomnia in Long-Term Care Facility Residents in Italy: A Double-Blind, Placebo-Controlled Clinical Trial. Journal of the American Geriatric Society, 2011; 59: 82-90.
  112. Hornyak M, Voderholzer U, Hohagen F, et al. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. 1998 Aug 1;21(5):501-5.
  113. Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011 Oct 19;31(42):14871-81.
  114. Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan 28;65(2):165-77.
  115. Song CH, Kim YH et al. Associations of Zinc and Copper Levels in Serum and Hair with Sleep Duration in Young Women. Biological Trace Element Research, 2012.
  116. Huss M, Volp A, and Stauss-Grabo M. upplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study. Lipids Health Dis. 2010 Sep 24;9:105.
  117. Fernandez-San-Martin MI, Masa-Font R et al. Effectiveness of Valerian on Insomnia: A Meta-Analysis of Randomized Control Trials. Sleep Medicine, 2010; 11: 505-11.
  118. [No authors listed]. Monograph. Valerianaofficinalis. Altern Med Rev. 2004 Dec;9(4):438-41.
  119. Ziegler G, Ploch M, Miettinen-Baumann A, et al. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia--a randomized, double-blind, comparative clinical study. Eur J Med Res. 2002 Nov 25;7(11):480-6.
  120. Gutierrez S, Ang-Lee MK, Walker DJ, et al. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. PharmacolBiochemBehav. 2004 May;78(1):57-64.
  121. Anderson GD, Elmer GW et al. Pharmacokinetics of Valerenic Acid After Single and Multiple Doses of Valerian in Older Women. Phytotherapy Research, 2010; 24: 1142-6.
  122. Sanchez-Ortuno MM, Bélanger L, Ivers H, et al. The use of natural products for sleep: A common practice? Sleep Med. 2009 Oct;10(9):982-7.
  123. Zick SM, Wright BD et al. Preliminary Examination of the Efficacy of Safety of a Standardized Chamomile Extract for Chronic Primary Insomnia: A Randomized Placebo-Controlled Pilot Study. BMC Complementary and Alternative Medicine, 2011; 11: 78.
  124. Shinomiya K, Inoue T et al. Hypnotic Effects of Chamomile and Passiflora Extracts in Sleep-Disturbed Rats. Biological Pharmacology Bulletin, 2005; 28(5): 808-10.
  125. Dahwan K, Dhawan S et al. Passiflora: A Review Update. Journal of Ethnopharmacology, 2004; 94: 1-23.
  126. Nassiri-Asl M, Shariati-Rad S et al. Anticonvulsant Effects of Arial Parts of Passifloraincarnata Extract in Mice: Involvement of Benzodiazepine and Opioid Receptors. BMC Complementary and Alternative Medicine, 2007; 8(7): 26.
  127. Dahwan K, Kumar S et al. Comparative Anxiolytic Activity Profile of Various Preparations of Passiflora incarnate Linneaus: A Comment on Medicinal Plants' Standardization. The Journal of Complementary and Alternative Medicine, 2002; 8(3): 283-91.
  128. Appel K, Rose T, Fiebich B, et al. Modulation of the γ-aminobutyric acid (GABA) system by Passifloraincarnata L. Phytother Res. 2011 Jun;25(6):838-43. doi: 10.1002/ptr.3352.
  129. Dhawan K, Dhawan S, and Chhabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of PassifloraincarnataLinneaus: a non-habit forming anxiolytic. J Pharm Pharm Sci. 2003 May-Aug;6(2):215-22.
  130. Archana R and Namasivayam A. Antistressor Effect of Withania somnifera. Journal of Ethnopharmacology, 1999; 64; 91-93.
  131. Bhattacharya SK, Bhattacharya A et al. Anxiolytic/Antidepressant Activity of WithaniaSomniferaGlycowithanolides: an Experimental Study. Phytomedicine, 2000; 7(6): 463-9.
  132. Kumar A and Kalonia H. Protective effect of WithaniasomniferaDunal on the behavioral and biochemical alterations in sleep-disturbed mice (Grid over water suspended method). Indian J Exp Biol. 2007 Jun;45(6):524-8.
  133. Kumar a, Kalonia H. Effect of Withania somnifera on Sleep-Wake Cycle in Sleep-Disturbed Rats: Possible GABAergic Mechanism. Indian J Pharm Sci. 2008;70(6):806-10.
  134. Raines T, Jones P et al. Investigation of the Anxiolytic Effects of Luteolin, A Lemon Balm Flavonoid in the Male Sprague-Dawley Rat. AANA Journal, 2009; 77(1): 33-36.
  135. Weeks BS. Formulations of Dietary Supplements and Herbal Extracts for Relaxation and Anxiolytic Action: Relarian. Medical Science Monitor, 2009; 15(11): 256-62.
  136. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med, 2004; 66(4): 607-13.
  137. Muller SF and Klement S. A Combination of Valerian and Lemon Balm is Effective in the Treatment of Restlessness and Dyssomnia in Children. Phytomedicine, 2006; 13: 383-7.
  138. Chien LW, Cheng SL et al. The Effect of Lavendar Aromatherapy on Autonomic Nervous System in Midlife Women with Insomnia. Evidence Based Complementary and Alternative Medicine, 2012: 1-8.
  139. Lewith GT, Godfrey AD et al. A Single-Blinded, Randomized Pilot Study Evaluating the Aroma of Lavandulaaugustifolia as a Treatment for Mild Insomnia. The Journal of Alternative and Complementary Medicine, 2005; 11(4): 631-7.
  140. Hirokawa K, Nishimoto T et al. Effects of Lavender Aroma on Sleep Quality in Healthy Japanese Students. Perceptual and Motor Skills, 2012; 114(1): 111-122.
  141. Kim JH, Desor D et al. Efficacy of as1-casein hydrolysate on stress-related symptoms in women. European Journal of Clinical Nutrition, 2007; 61: 536-541.
  142. Saint-Hilaire Z, Messaoudi M et al. Effects of a Bovine Alpha S1-Casein TrypticHydrosylate (CTH) on Sleep Disorder in Japanese General Population. The Open Sleep Journal, 2009; 2: 26-32.